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Got	 to	 thank	 my	 social	 network	 for	 schticking	 around,	 and	 gracefully	 and	
sarcastically	shoot	me	down	when	my	intricate	stories	of	genomic	islands,	spooky	





















avoid	 the	 spread	 of	 infectious	 agents	 by	 stopping	 transmission	 through	
surveillance	and	appropriate	containment	measures.	We	want	to	understand	the	
basal	biological	processes	explaining	how	pathogens	spread,	produce	disease,	and	
evade	 treatment.	 Pathogen	 discovery,	 surveillance	 and	 disease	 prevention	 has	
evolved	and	matured	greatly	through	the	latest	centuries	(1),	and	the	problems	
we	 encounter	 today	 and	 the	methods	we	 use	 to	 solve	 them	 are	 both	 in	 rapid	
change.	 Infections	 is	 a	major	 cause	 of	morbidity	 and	mortality	 in	 humans,	 and	









particularly	 adapted	 to	 persist	 in	 health	 care	 facilities	 and	 cause	 disease	 in	
patients	with	other	serious	conditions	who	otherwise	enjoys	the	best	and	most	
advanced	treatment	modern	health	care	is	able	to	provide.		
The	 research	 presented	 in	 this	 thesis	 focus	 on	 basal	 biological	 processes	
governing	the	spread,	evolution	and	resistance	to	treatment	in	enterococci,	and	










today,	 E.	 faecium	 and	 E.	 faecalis,	 the	 two	 enterococci	 most	 prone	 to	 causing	
infections	 in	humans,	weren’t	considered	 two	different	species	before	 the	mid-





identified	 as	 parts	 of	 the	 human	 intestinal	microbiota,	 we	 now	 know	 them	 as	
ubiquitous	 in	 nature	 (12).	 Found	 in	 and	 on	 other	 animals,	 insects	 and	 fish,	 on	
plants,	 in	water	and	 food,	we	now	know	of	54	 species	within	 the	Enterococcus	
genus	(12–19).	Most	of	them	have	been	characterized	during	the	last	20-30	years.	




Historically,	 enterococci	 has	 been	 isolated	 predominantly	 as	 causes	 of	
bacteraemia,	endocarditis	and	UTIs	(20).	Enterococci	are	also	capable	of	invading	
other	foci	as	an	opportunistic	pathogen,	if	a	patient’s	ability	to	clear	the	infection	
has	 been	 compromised.	E.	 faecium	has	 been	 included	 as	 one	 of	 the	 five	major	
multi-resistant	pathogens	predominantly	causing	the	lion’s	share	of	nosocomial	
infections	–	the	ESKAPE	pathogens	–	the	other	ones	being	Staphylococcus	aureus,	
Klebsiella	 pneumoniae,	 Acinetobacter	 baumanni,	 Pseudomonas	 aeruginosa	 and	
Enterobacter	species	(21).	The	complexities	of	modern	medicine	lead	to	a	severely	
compromised	immune	defence	in	many	patients	for	many	treatments.	Enterococci	
and	 E.	 faecium	 in	 particular	 have	 become	 increasingly	 prevalent	 as	 causes	 of	










cephalosporins	 in	 U.S.A.,	 of	 which	 enterococci	 are	 naturally	 resistant	 (25).	 In	
Europe,	vancomycin	resistant	enterococcus	(VRE)	occurrence	has	been	linked	to	





which	 mostly	 has	 occurred	 in	 E.	 faecium	 (27).	 The	 latest	 systemic	 surveys	




Causal	 factors	 of	 pathogenicity	 and	 virulence	 in	 E.	 faecium	 has	 to	 be	 seen	 in	
connection	 to	 the	 extensive	 resistance	 levels	 this	 species	 demonstrates	 when	
encountered	 in	 hospital	 settings,	 permitting	 survival	 and	 transfer	 to	 patients	
susceptible	to	infection.	No	single	defining	virulence	factor	has	been	identified	in	
E.	 faecium,	 but	 several	 genes	 are	 enriched	 in	 clinical	 lineages	 that	 may	 aid	 in	
invasiveness.	 As	 an	 opportunistic	 pathogen	 mostly	 causing	 severe	 disease	 in	
immunocompromised	 hosts,	E.	 faecium	 has	 proven	 to	 be	 elusive	 to	 accurately	
characterise	in	terms	of	virulence.		
It	 is	 difficult	 to	 assess	 the	 contribution	 of	 any	 particular	 putative	 virulence	













with	 two	 different	 phosphotransferase	 systems	 (PTS)	 are	 associated	 with	




more	 comprehensive	 pathogenesis	 model	 would	 require	 examining	 the	 whole	










occur	 and	 what	 consequence	 they	 confer	 is	 a	 complex	 subject,	 and	 some	
controversy	exists	over	whether	dysbiosis/imbalance	is	a	satisfactory	explanation	
or	 whether	 other	 models	 need	 to	 be	 used	 in	 order	 to	 gauge	 how	 bacterial	
composition	 in	 the	 gut	 contributes	 to	 human	 diseases	 (44,	 45).	 Outside	 the	
hospital	 and	 the	 selective	 effect	 of	 antimicrobial	 exposure,	E.	 faecium	 from	 the	








gut	 flora	 as	 a	 result	 of	 broad-spectrum	 antibiotic	 use,	 thereby	 facilitating	 host	
invasion.	They	experimented	on	a	 feedback-loop	where	Paneth	 cells	 in	 the	 gut	
lining	 excretes	 an	 antimicrobial	 peptide	 with	 activity	 against	 Gram-positive	
bacteria	called	RegIIIγ	in	response	to	presence	of	lipopolysaccharides	originating	
from	Gram-negative	bacteria	(48).	When	Gram-negative	bacteria	are	cleared	from	





and	concurrent	antimicrobial	 treatment,	with	host	 factors	segregating	 from	the	
gut	wall	and	creating	an	extracellular	matrix	around	the	VRE	to	protect	the	gut	
epithelium.	 The	 apical	 cell	 wall	 mucus	 layer	 thickness	 decreased	 during	 VRE	
dysbiosis.	 Epithelial	 architecture	 was	 also	 altered,	 which	 they	 were	 able	 to	
connect	 to	 intraluminal	 biochemical	 changes	 resulting	 in	 displacement	 of	
intercellular	 adherence	 junctions	 from	 the	 cell	wall	 to	 the	 extracellular	matrix	
surrounding	 the	 VRE.	 All	 these	 intra-luminal	 changes	were	 clinically	 observed	
only	as	mild	non-inflammatory	diarrhoea.		
Enterococci	 inhabit	a	crowded	environment	inside	the	human	gut	and	compete	
with	 other	 species	 to	 survive.	 Their	 low	 virulence	 in	 immunocompetent	 hosts	
perturbs	 clear	 assertions	 of	 whether	 enterococci	 and	 their	 hosts	 co-exists	 in	
antagonistic,	neutral	or	synergistic	fashion	(50).	In	fact,	VRE	introduced	prior	to	
induced	 cecal	 puncture	 giving	 a	 polymicrobial	 invasive	 infection	 actually	
protected	 mice	 by	 giving	 lower	 polymicrobial	 bacterial	 loads,	 milder	
inflammatory	reactions	and	swifter	recovery	compared	to	VRE	negative	control	
mice	 (51).	 E.	 faecium	 excretes	 the	 biofilm-associated	 peptidoglycan	 hydrolase	
SagA	 (52),	 which	 according	 to	 recent	 studies	 is	 able	 to	 prevent	 Salmonella	
pathogenesis	through	degrading	parts	of	the	Salmonella	cell	wall	(53).	These	cell	
wall	 fragments	 induce	 changes	 in	 the	 immunological	 pathways	 of	 the	 gut	
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(62).	 Enterococci	 are	 in	 vivo	 resistant	 to	 clindamycin	 by	 efflux	 pumps,	
trimethoprim-sulfamethoxazole	by	missing	target,	and	clinically	achievable	levels	
of	most	aminoglycosides	due	to	enzymatic	degradation	(56,	63).	E.	 faecium	has	
also	 swiftly	 gained	 resistance	 through	 mutations	 or	 by	 acquiring	 resistance	




to	 have	 had	 synergistic	 effect	 as	 long	 as	 the	 bacterium	 does	 not	 harbour	 any	
additional	 gentamicin	 resistance	 determinants	 providing	 high-level	 resistance	
(60,	69–71),	 and	has	been	 considered	 standard	 treatment	 for	decades.	Mobile-
element	 located	 enzymes	 modifying	 aminoglycosides	 are	 widespread	 in	
enterococci	 (60,	 72),	 effectively	 obstructing	 the	 ampicillin	 plus	 gentamicin	





Vancomycin	 was	 isolated	 from	 Amycolatopsis	 orientalis	 in	 1953	 as	 a	 cell	 wall	
compound	active	against	Gram-positives,	but	was	considered	secondary	to	other	
antimicrobials	 with	 better	 bactericidal	 effects,	 and	 as	 initially	 thought,	 better	
toxicity	 profiles	 (73).	 This	 changed	 in	 the	 70s	 and	 80s,	 as	 ß-lactam-resistant	


















as	 a	 last-resort	 antibiotic	 when	 other	 options	 were	 depleted.	 Vancomycin’s	
glycopeptide	cousin,	teicoplanin,	was	also	introduced	in	this	period	(76,	77),	and	




transpeptidases	 (82).	 Vancomycin	 attaches	 to	 D-ala-D-ala	 through	 a	 hydrogen	
bond	 and	 denies	 transpeptidases	 to	 access	 peptidoglycans	 and	 thus	
polymerisation	(82),	see	Figure	2.	Vancomycin	is	a	big	molecule	largely	inefficient	
as	an	antimicrobial	 towards	Gram-negative	pathogens	since	 it	cannot	cross	 the	
Gram-negative	outer	membrane,	but	 recent	 research	on	vancomycin	analogues	
show	 that	 increasing	 polarity	 through	modification	may	 circumvent	 this	 issue	
(83).		
Vancomycin	 became	 increasingly	 used	 in	 the	 80s,	 and	 the	 first	 reports	 of	 a	
vancomycin-resistant	 E.	 faecium	 (VREfm)	 outbreak	 (84)	 and	 first	 described	
occurrence	of	a	plasmid-mediated	vancomycin	resistance	determinant	(85)	(both	
in	1988)	signalled	a	development	to	the	troubling	situation	we	have	today.	The	
dissemination	 of	 vancomycin-resistant	 E.	 faecium	 occurred	 swiftly	 in	 North	
American	 hospitals	 after	 that	 initial	 outbreak,	 while	 the	 later	 vancomycin	
resistance	spread	 in	Europe	has	been	associated	 to	 the	use	of	 the	glycopeptide	
avoparcin	as	a	growth	promoter	in	farms	(86–88).	North	America	still	experiences	
higher	 prevalence	 of	 vancomycin	 resistance	 in	 clinical	 isolates	 compared	 to	
Europe,	 as	 seen	 in	 the	 point	 prevalence	 figure	 obtained	 from	
resistancemap.cddep.org	and	earssnet.org	(Figure	1).			
E.	 faecium,	 called	a	 “drug	resistance	 trafficker”,	has	acquired	no	 less	 than	eight	
different	 vancomycin	 resistance	 gene	 clusters	 –	 vanA,	 vanB,	 vanD,	 vanE,	 vanG,	
vanL,	vanM	and	vanN	 to	defend	itself	(89–92).	Additionally,	a	vanC	gene	cluster	

















VanA/B	 adds	 D-lac	 as	 the	 terminal	 peptide	 (93).	 See	 Figure	 2	 for	 graphical	
depiction	of	the	VanA	resistance	mechanism	and	variations	in	operon	structure	of	
some	 of	 the	 vancomycin	 resistance	 clusters	 encountered	 in	 enterococci.	 The	
terminal	peptide	alteration	provides	significant	reduction	in	glycopeptide	binding	
affinity.	D-ala-D-lac	provides	higher	resistance	level	than	D-ala-D-ser.	Vancomycin	
resistance	 generally	 occurs	 via	 activation	 of	 resistance	 effectors	 by	 a	 feedback	
loop	 consisting	 of	 a	 sensor	 (VanS)	 that	 phosphorylates	 a	 regulator/activator	
(VanR)	when	vancomycin	is	present.	Phosphorylated	VanR	subsequently	binds	to	
nucleotides	 in	 vicinity	 of	 the	 promoters	 of	 the	 resistance	 effector	 genes,	 and	
activates	transcription.	Vancomycin	resistance	itself	is	mediated	by	several	genes	
(vanH/T,	 vanA/B/C/D/E/G/L/M/N	 and	 vanX)	 that	 when	 expressed	 forms	 a	
pathway	replacing	D-ala-D-ala	to	D-ala-D-lac	(or	D-ala-D-ser).	In	addition	to	these	






in	 clinical	 isolates	 (22).	Globally,	vanA	 has	been	 and	 is	 still	 the	most	 abundant	
resistance	cluster	in	clinical	isolates,	whereas	vanB	has	increasingly	been	found	
the	 last	 decade	 in	 Europe,	 and	 is	 the	 most	 abundant	 vancomycin	 resistance	
mechanism	 found	 in	 Australia	 (22,	 23,	 96).	 They	 are	 associated	 with	 mobile	
genetic	 elements.	 The	 vanA	 gene	 cluster	 is	 normally	 part	 of	 the	 Tn3-family	
transposon	Tn1546	(89)	and	the	most	prevalent	vanB	subtype	is	an	integral	part	
of	 the	 integrative	conjugative	element	Tn1549/5382	(61,	97).	This	may	explain	






recently	 approved	 drugs	 for	 which	 E.	 faecium	 often	 show	 susceptibility	 have	
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entered	 into	 treatment	recommendations	 to	clear	VRE	 infections.	Thus,	several	




ß-lactams.	 Resistance	 towards	 daptomycin	 has	 been	 shown	 to	 arise	 through	
mutations	in	genes	associated	with	cell	membrane	construction	pathways	(liaFSR,	





glycopeptides	but	are	 thought	 to	possess	 superior	bactericidal	action	by	closer	






describing	 oritavancin	 activity	 have	 not	 been	 published	 yet.	 Oritavancin	 is	
consequently	not	in	wide	therapeutic	use.		
Other	antimicrobials,	the	oxazolidinones	linezolid	and	tedizolid,	act	by	binding	to	
ribosomes	 and	 prohibiting	 mRNA-protein	 translation	 through	 abrogation	 of	
aminoacyl-tRNA	docking.	This	mechanism	ensures	bacteriostasis	 in	enterococci	
unless	specific	mutations	occur	in	the	23S	rRNA	gene.	Such	mutations	generally	
confer	 cross-resistance	 to	 linezolid	 and	 tedizolid	 (101).	 Enterococci	 possess	
several	copies	of	23S	rDNA,	and	become	increasingly	resistant	as	more	of	the	gene	
copies	 gain	 these	 mutations.	 The	 horizontally	 transmissible	 resistance	
determinants	cfr	and	optrA,	respectively	encoding	an	rRNA	methylase	conferring	
resistance	to	 	 linezolid	and	an	ABC	transporter	pumping	out	both	 linezolid	and	
tedizolid	have	also	been	found	in	enterococci	(102,	103).		
Streptogramins	also	attack	the	ribosome	through	binding	to	the	50S	subunit,	and	
the	 two	drugs	dalfopristin	and	quinopristin	 (Q/D)	are	delivered	 together	 since	
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they	synergistically	provide	bactericide	by	irreversible	inhibition	of	the	ribosome.	
Resistance	 towards	 Q/D	 is	 mediated	 by	 multiple	 identified	 resistance	
determinants	that	alter	the	ribosome,	provide	hindrance	to	target,	pump	Q/D	out	
of	 the	cell	or	break	either	one	or	both	Q	and	D	 thus	hampering	 the	synergistic	
effects	and	therefore	bactericide.		
Tigecycline	 also	 binds	 to	 the	 ribosomal	 subunit	 16S	 and	 prohibits	 docking	 of	
aminoacyl-transfer	RNA	resulting	in	translation	halt.	Reservations	against	the	use	
of	this	drug	has	arisen	since	it	has	a	high	volume	of	distribution,	which	causes	low	






In	E.	 faecium,	 resistance	development	seems	 to	occur	 in	an	additive	manner	 in	
which	 certain	 strains	 amass	 one	 resistance	 determinant	 after	 another,	 while	
others	 stay	 susceptible	 and	 easier	 to	 manage	 during	 infection.	 As	 mentioned	














Figure	 3.	Mechanisms	 by	 which	 multiple	 resistance	 (MDR)	 patterns	 arise	 in	
bacteria	(A->D)	as	well	as	their	dissemination	and	persistence	within	susceptible	
bacterial	 communities	 (E->I).	 Resistance	 genes	 or	 gene	 clusters	 may	 confer	
resistance	 to	 multiple	 antibiotics	 or	 even	 multiple	 classes	 of	 antibiotics,	 here	
exemplified	by	a	multi-drug	efflux	pump	(A).	Diverse	resistance	mechanisms	often	co-
reside	on	MGEs	and/or	in	proximity	on	the	chromosome,	and	are	co-inherited	(B).	High	
mutation/recombination	 rates	 permit	 swifter	 acquisition	 of	 resistance	 trough	
mutations	 or	 horizontally	 transferred	 DNA	 (C),	 but	 may	 also	 be	 an	 effect	 of	
antimicrobial	exposure	since	bacterial	stress	increases	mutation	rates.	The	“slippery	











be	 positive	 (leading	 to	 better	 fitness)	 in	 MDR	 strains	 compared	 to	 single-resistant	
strains	 (G).	 Niche	 differentiation	 (H)	 refers	 to	 MDR	 bug	 proliferation	 in	 niche	
environments	(such	as	hospitals)	that	contain	frequent	exposure	to	selecting	stressors	








during	 treatment	 for	 other	 infections	 is	 intuitively	 a	 present	 factor.	 Use	 of	
antimicrobials	 is	 more	 densely	 occurring	 in	 hospitals	 than	 in	 the	 community,	
which	 may	 explain	 how	 high-risk	 E.	 faecium	 clones	 are	 often	 found	 in	 health	
institutions.	 As	 demonstrated	 by	Brandl	 et	 al.	 and	Hendrickx	 et	 al.	 (47,	 49),	E.	
faecium	 has	 a	 potential	 of	 ‘taking	 over’	 the	 gut	 during	 broad	 spectrum	
antimicrobial	 treatment	 as	 other	 bacteria	 succumb	 to	 the	 treatment	 while	 E.	
faecium	survives.	Finally,	a	host	and	a	resistance	gene	containing	element	may	co-
evolve	to	alleviate	any	 initial	 fitness	cost	 introduction	of	 the	element	may	have	
burdened	the	host	with	(108,	109).		
Horizontal	gene	transfer	and	mobile	genetic	elements	
E.	 faecium	 is	 considered	 a	master	 of	HGT	 and	 understanding	 how	 genes	move	
around	in	the	bacterial	population	and	which	traits	they	confer	is	a	complex	but	
important	 task	 in	 order	 to	 reveal	 their	 basal	 biology.	Mobile	 genetic	 elements	
blend	in	a	Pandora’s	box	where	multiple	movement	mechanisms	often	co-exist	in	
vicinity	 of	 each	 other,	 creating	multiple	 recombination-	 and	 gene	 arrangement	
possibilities.		
HGT	as	a	phenomenon	 is	a	 large	 field	 to	embrace	 in	some	small	 sentences	and	
paragraphs,	and	has	to	be	seen	in	the	larger	scope	than	the	spread	of	antimicrobial	
resistance	and	putative	virulence	genes	(110).	If	we	consider	any	stretch	of	DNA	
as	 under	 selection,	 following	 the	 thinking	 of	 Dawkins’	 selfish	 gene	 (111)	 or	
Baquero’s	term	‘piece’	–	an	ordered	structure	that	forms	part	of	a	separate	higher-
ordered	structure	(112)	–	HGT	enlarges	the	‘playground’	in	which	any	DNA	is	able	
to	 exist,	 and	 contribute	 to	 disseminate	 genetic	 structures	 throughout	 different	
lifeforms.	Indeed,	horizontal	transfer	is	shown	as	the	primary	driver	of	expansion	
of	protein	families	through	prokaryotes	as	opposed	to	slower	processes	like	gene	
duplication	 and	 subsequent	 specialisation	 (113).	 The	 transferred	 genetic	
structures	themselves	often	seem	to	code	for	peripheral	functions	predominately	
under	neutral	selection	(114)	and	tend	in	aggregate	to	be	less	expressed	than	core	
genes	 to	mitigate	 the	 potential	 for	 reduced	 fitness	 in	 hosts	 that	 harbour	 them	





and	 cytosines	 compared	 to	 adenines	 and	 thymines),	 and	 these	 two	 traits	
represent	the	largest	barrier	of	HGT	between	different	strains	and	species	(118).		
	
Taking	 this	 discussion	 down	 to	 the	 ground	 again,	 several	 mechanisms	 are	
responsible	for	shuttling	genes	from	one	bacterium	to	another,	and	those	will	be	
briefly	explained.	In	addition,	specific	MGE	types	like	plasmids,	transposons,	ICEs	
and	 so	 forth	 will	 conceptually	 be	 described.	 Furthermore,	 bacterial	 immune	
defences	affecting	the	dynamics	by	which	MGEs	may	or	may	not	enter	and	survive	











• Transduction	 happens	 when	 DNA	 is	 trapped	 within	 bacteriophages	
(bacterial	viruses)	that	have	infected	a	host,	and	is	released	and	inserted	
into	the	genome	of	a	new	host	after	bacteriophage	transmission.		










functional	 explanation.	 There	 are	 several	 system	 variants	 as	 determined	 by	
comparison	 of	 T4SS	 from	 Gram-positive,	 Gram-negative	 and	 mobile	 element	
sources	 (123–126),	 but	most	 systems	 share	 some	basal	 common	 features.	 The	
process	 of	 conjugation	 starts	 with	 nicking	 the	 double-stranded	 (ds)	 DNA	 into	
single-stranded	(ss)	DNA	by	a	relaxase,	often	referred	to	as	a	MOB	protein.	The	
relaxase	 recognises	 a	 specific	 site,	 the	 origin	 of	 transfer	 (oriT),	which	must	 be	
present	 for	 initiation	 of	 transfer	 to	 occur	 (127).	 	 See	 Figure	 4.	 Using	 the	
nomenclature	of	the	model	T4SS	found	in	Agrobacterium	tumefaciens,	the	relaxase	
then	 interacts	with	 a	 Type	 4	 Coupling	 Protein	 (T4CP),	 called	 VirD4.	 VirD4,	 an	













are	often	present	 in	many	copies	within	a	bacterial	 cell,	 and	are	 referred	 to	as	
“cryptic”	meaning	that	there	is	no	apparent	functional	benefit	to	harbour	them.	
Plasmids	that	are	more	complex	contain	additional	genes	encoding	functions	such	
as	 antimicrobial	 resistance	 genes,	 stability	 modules	 (discussed	 below)	 and	
conjugation	modules.	 They	 need	 other	 mechanisms	 to	 persist	 in	 the	 cell	 than	
smaller	 ones,	 and	by	 looking	 at	 gene	 content,	 are	more	 likely	 to	 contain	 genes	
encoding	central	functions	to	their	hosts	survival	(127).	Plasmids	are	conjugative	
when	they	encode	the	T4SS	described	above,	and	mobilisable	if	they	contain	oriT	
and	 parts	 of	 the	 conjugation	 apparatus,	 most	 commonly	 the	 relaxase	 and	
sometimes	 a	T4CP.	Recent	 compilations	 of	 plasmid	 sequences	 and	 attempts	 to	
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strand	Rolling	Circle	Replication	 (RCR)	 and	bi-directional	Theta	 (q)	 replication	
(130,	131).	RCR	plasmids	are	often	cryptic	and	small,	as	this	replication	method	is	
prone	 to	 mistakes	 and	 becomes	 unstable	 when	 they	 are	 over	 10-15	 kb.	 q-
replicating	plasmids	are	subdivided	into	replicon	families	in	enterococci;	Rep_3,	
Inc18	 and	RepA_N.	 Briefly,	 Rep_3	 plasmids	 are	 narrow	host	 range	 plasmids	 of	
similar	size	as	RCR	plasmids	and	 likewise	are	often	cryptic.	 Inc18	plasmids	are	
often	 conjugative	 25-50	 kb	 broad	 host-range	 plasmids	 frequently	 harbouring	
resistance	determinants.	RepA_N	plasmids	are	prevalent	in	low	GC	content	Gram-
positives,	and	are	present	in	a	wide	size	range	(10-300	kb).	Individual	plasmids	
show	 a	 narrow	 host	 range.	 This	 classification	 scheme	 is	 often	 disturbed	 by	




Ever	 since	Barbara	McClintock	discovered	 genes	which	only	 apparent	 function	
was	to	encode	their	own	transposition	(movement)	from	one	genomic	location	to	
another	(136),	multiple	classes	of	transposable	elements	using	a	diverse	array	of	
transfer	 mechanisms	 located	 throughout	 all	 lifeforms	 including	 bacteria	 have	
been	 described	 (137).	 As	 extensively	 reviewed	 by	Darmon	&	 Leach	 (137)	 and	
Siguier	et	al.	(138),	transposases	come	in	many	shapes	and	forms	in	bacteria,	and	
combine	 to	 create	 an	 enormous	 amount	 of	 elements	 able	 to	 jump	 around	 the	
genome	 through	diverse	mechanisms.	The	basal	unit	of	mobile	elements	 is	 the	
transposase	(Tnp)	itself.	Tnps	normally	binds	to	specific	 inverted	(IR)	or	direct	
(DR)	repeats	up-	and	downstream	of	the	tnp	gene,	and	excises	and	integrates	the	
region	between	 the	 repeats	by	 two	main	mechanisms	–	cut-and-paste	or	copy-
and-paste.	Tnps	are	organized	 into	different	 families	based	on	their	properties.	
First	and	foremost	is	the	active	protein	site	cleaving	DNA	during	transposition,	of	
which	 there	 are	 five	 main	 motifs:	 DDE,	 DEDD,	 HUH,	 and	 site-specific	
transposases/resolvases	 containing	 serine	 or	 tyrosine	 in	 the	 active	 site	 [also	
functionally	 reviewed	 (139,	 140)].	 General	 mode	 of	 transposition,	 length	 and	




A	 unit	 transposon	 carries	 passenger	 genes	 in	 addition	 to	 the	 tnp	 within	 the	
IRs/DRs.	Composite	transposons	are	recognised	by	two	transposons	of	the	same	
IS	family	surrounding	a	stretch	of	DNA	containing	genes,	which	may	be	passengers	
if	 the	 transposase	 recognises	 the	 IR’s	 on	 either	 side	 and	 thus	 moves	 both	 IS	
elements	and	the	intermediate	DNA	stretch.		
Mobile	 elements	may	 grow	 even	 larger,	 engulfing	multiple	 passenger	 genes	 or	
even	 complete	 pathways	 of	 gene	 clusters	 supporting	 complex	 functions.	 These	
larger	 elements,	 often	 called	 genomic	 islands	 (GIs),	 integrative	 conjugative	
elements	(ICEs)	if	they	are	conjugative	or	integrative	mobilisable	elements	(IMEs)	
if	they	are	able	to	hitch-hike	with	other	conjugative	systems,	are	very	diverse	and	
likely	 more	 prevalent	 in	 nature	 than	 currently	 shown	 as	 we	 still	 struggle	 to	
identify	 them	 (141).	 Evidence	 suggests	 that	 ICEs	may	 be	more	 abundant	 than	
conjugative	plasmids	in	prokaryotes	(142).	ICEs	and	IMEs	most	often	demonstrate	







race	where	both	parties	 harbour	mechanisms	designed	 to	defend	 against	MGE	
inclusion	 for	 the	 bacterial	 host,	 or	 ensuring	 persistence	 for	 the	 MGE.	 These	
systems	may	also	demonstrate	other	functions	in	the	cell,	which	introduces	exiting	




Toxin-Antitoxin	 (T/A)	 systems,	 also	 called	 post-segregational	 killing	 systems,	
consist	of	a	T/A	pair	designed	to	kill	 the	bacterium	if	 the	genes	encoding	them	
become	segregated	(that	 is:	 lost)	 from	the	genome.	This	works	as	 the	antitoxin	
inhibits	toxin	function,	but	is	inherently	less	stable	in	the	cell	than	the	toxin.	As	the	
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antitoxin	 binding	 to	 toxin	 for	 inhibition:	 	 mRNAantitoxin/mRNAtoxin	 (Type	 1),	
proteinantitoxin/proteintoxin	 (Type	 2),	 and	 mRNAantitoxin/proteintoxin	 (Type	 3),	
antitoxin	binding	to	toxin	substrates	(type	4),	and	antitoxin	degrading	the	toxin	
(143,	144).	Even	though	T/A	systems	were	originally	associated	with	MGEs	as	a	
factor	 ensuring	 their	 persistence	 in	 cells,	 T/A	 systems	 are	 also	 found	 in	
chromosomes	of	bacteria	without	association	to	MGEs.	This	surprising	finding	has	
led	to	a	nuanced	view	of	T/A	systems	function,	as	they	also	seem	to	be	a	part	of	
down-regulating	 cell	 growth	 and	division	under	 stressful	 conditions,	 apoptosis	
and/or	other	cellular	processes	 (144).	Type	2	T/A-systems	 found	 in	E.	 faecium	
includes	Axe/Txe	and	omega/epsilon/zeta	(145,	146).	These	plasmid-located	T/A	





















unmethylated	 foreign	 DNA	will	 be	 cleaved	 at	 arrival	 (152–154).	 This	 genomic	
defence	is	only	active	as	long	as	the	invading	MGE	does	not	succeed	in	inhabiting	
the	 cell	 for	 long	 enough	 to	methylate	 its	 restriction-susceptible	 sites	 therefore	
becoming	immune	(155).	R/M	systems	are	also	found	on	many	MGE	types,	and	
are	then	thought	 to	act	as	post-segregational	killing	systems	by	killing	the	new	
host	 if	 it	 doesn’t	 allow	 persistence	 of	 the	 acquired	MGE	 by	methylation	 of	 its	
chromosome	(150,	156).	This	“genetic	addiction”	also	appear	to	alter	dynamics	of	
movement	of	MGEs	through	bacterial	populations	(157).	Type	II	methylases	are	
frequently	 found	 without	 their	 corresponding	 restriction	 enzyme,	 and	 these	




Clustered	 Regularly	 Interspaced	 Short	 Palindromic	 Repeats	 (CRISPR)	 and	 Cas	
enzymes	 work	 by	 cleaving	 foreign	 DNA	 and	 RNA	 through	 sequence	 specific	
cleavage	 by	 Cas	 nucleases	 through	 hybridization	 of	 guiding	 sequences	
(spacers/crRNA)	to	the	DNA	or	RNA,	see	review	by	Hille	&	Charpentier	(159).	The	
CRISPR	region	consists	of	short	sequences	bearing	high	identity	to	DNA/RNA	of	
phages	and	conjugative	elements	previously	encountered	by	 the	 isolate	and	 its	
ancestors.	Spacers	are	separated	by	short	repeat	sequences	that	serve	to	separate	
each	unique	spacer	through	cleavage	of	the	fully	transcribed	CRISPR	array,	and	to	
provide	 interaction	 with	 the	 Cas	 nuclease	 apparatus.	 In	 addition	 to	 adaptive	
immune	defence,	CRISPR-Cas	has	also	been	implicated	in	DNA	repair	(160,	161),	
gene	 regulation	 (162)	 and	 structural	 genomic	 rearrangements	 (163)	 by	
containing	self-recognising	spacers.	This	would	imply	that	bacteria	are	prone	to	





negatively	 correlated,	 of	 which	 the	 answer	 seems	 to	 be	 no	 (166).	 Conversely,	
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CRISPR-Cas	 presence	 and	 activity	 is	 positively	 associated	 with	 resource	
availability	 (food)	 (167)	 and	 inversely	 correlated	 to	 mesophilic	 (temperate	
habitat)	 lifestyle	 (167,	 168).	Authors	 suggests	mutation	 rate	 is	 correlated	with	
temperature,	as	bacteria	and	MGEs	in	mesophilic	environments	are	more	rapidly	








they	 evolve.	 Unlike	 us,	who	 seemingly	 only	 accumulate	mutations	 through	 the	





This	aspect	 thus	 initiate	 thoughts	of	 a	 concept	where	we	no	 longer	merely	are	
interested	in	whether	there	is	an	E.	faecium	infection	or	not,	but	also	which	isolate.	
Can	this	isolate	be	related	to	other	isolates	also	causing	infection?	Does	it	contain	
specific	 traits	 able	 to	 at	 least	 give	 some	 indication	 of	 why	 exactly	 this	 isolate	
invaded	a	patient	and	caused	serious	problems?		
Being	able	to	answer	some	of	these	questions	require	the	help	of	certain	methods.	
Pathogen	 surveillance	 obviously	 require	 recording	 data	 of	 when	 and	 where	 a	
pathogen	 caused	 an	 infection	 to	 seed	 suspicions	 of	 an	 outbreak	 –	 that	 one	
particularly	virulent	bug	was	able	to	disseminate	itself	to	several	patients	from	a	
common	source.	Early	methods	 for	bacterial	 typing	 included	phenotypic	typing	
systems	 using	 serotypes,	 biotypes,	 phage-types	 and	 antibiograms	 (169).	 In	








Pulse-Field	 Gel	 Electrophoresis	 (PFGE)	 (170,	 171)	 has	 been	 the	 most	 widely	
adopted	 method	 in	 enterococcal	 outbreaks	 since	 the	 nineties.	 It	 involves	
immersing	isolate	cultures	in	agarose	plugs,	chemical	and	enzymatic	cell	lysis	and	
subsequent	 cutting	 of	 intact	 whole-genome	 DNA	 by	 a	 restriction	 enzyme	 that	
cleaves	DNA	 sequences	 in	 a	 sequence-specific	manner,	 ideally	 fragmenting	 the	




dyed,	 and	 the	 fragments	 appear	 as	 fingerprint	 patterns,	which	 can	 be	 directly	
compared	 to	 other	 isolates	 in	 the	 same	 gel.	 From	 there,	 comparison	 between	
bands	 (number	 of	 matches	 and	 relative	 size	 and	 presence/absence	 of	
mismatches)	is	used	to	determine	relatedness	by	defined	criteria	(170).		
Other	methods	 in	 the	 same	 “fingerprint”	 category	 includes	 amplified	 fragment	
length	 polymorphism	 (AFLP)	 (172)	 and	 restriction	 fragment	 length	
polymorphism	(RFLP)	(173)	which	are	variations	of	cutting	DNA	with	restriction	
enzymes	and	amplification	of	DNA	by	PCR.	Ribotyping	is	a	third	method,	involving	
cutting	 whole-genome	 DNA	 with	 restriction	 enzymes,	 perform	 a	 gel	
electrophoresis	 and	 then	 transfer	 the	 fragments	 onto	 a	 membrane	 (Southern	








between	 labs	 and	 maybe	 within	 labs,	 as	 well	 as	 difficulty	 assessing	 level	 of	
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difference	 between	 strains.	 Different	 methods	 needed	 to	 be	 used	 to	 address	
different	questions:	methods	with	high	discrimination	sensitivity	are	needed	to	




The	 most	 important	 early	 adoption	 of	 genomic	 global-scale	 comparisons	 of	
bacteria	on	strain	level	came	with	multi-locus	sequence	typing	(MLST)	(176),	first	
developed	for	Neisseria	meningitidis	and	later	adopted	to	many	other	bacteria.	The	
method	 is	 based	 on	 choosing	 seven	 house-keeping	 genes	 ideally	 dispersed	 as	
much	as	possible	throughout	the	bacterial	chromosome,	sequence	them,	and	then	
adopt	 them	 into	 an	 allele-based	 scheme.	 ‘House-keeping	 genes’	 refer	 to	 genes	
present	 in	 all	 strains	 of	 a	 species	 which	 are	 not	 super-conserved	 and	 never	
mutating,	and	not	actively	selected	upon	–	neutral	selection	pressure.	Each	allele	
is	assigned	a	number,	and	if	the	allele	in	your	gene	is	different	to	those	already	
present	 in	 the	 database	 by	 any	 means,	 it	 gets	 a	 new	 number.	 The	 allele	
combinations	combine	to	create	a	Sequence	Type	(ST),	which	clusters	by	number	
of	 allele	 differences	 between	 the	 STs.	 As	 clinical	 isolates	 are	 sequenced	 in	
increasing	 numbers,	 additional	 genes	 are	 included	 in	 these	 schemes	 to	 gain	
resolution.	Other	approaches	extending	 the	allele	comparison	principle	 include	
MLST	of	ribosomal	genes	(rMLST),	genes	common	to	all	or	most	of	the	isolates	of	













in	all	 isolates	 in	 the	dataset	 (the	core	genome	–	 interchangeable	with	common	
genes),	and	then	identify	individual	bases	that	are	different	between	the	isolates	
–	so-called	single-nucleotide	polymorphisms,	or	SNPs.	As	most	of	these	studies	use	
large	amounts	of	 isolates	sequenced	by	short-read	technologies	 like	 Illumina,	a	




several	 land-mark	papers	using	 this	 approach	 (179,	 180).	 It	 is	 also	possible	 to	
assemble	the	reads	to	obtain	whole	genome	sequences,	and	identify	common	DNA	











ClonalFrameML	 (185).	 The	 finished	 dataset	 of	 SNPs	 will	 then	 be	 fed	 into	 a	
phylogenetic	 software,	 of	 which	 there	 are	 several	 algorithms	 to	 choose	 from	
(178).		
Identifying	 common	 DNA	 content	 between	 strains	 is	 also	 possible	 to	 do	 by	
clustering	 genes	 by	 similarity,	 subsequently	 gaining	 a	 matrix	 of	 which	
encountered	genes	are	present	in	which	genomes	as	output	(186).	Size	of	the	core	
genome	 (genes	 present	 in	 all	 strains	 –	 interchangeable	 with	 common	 DNA	
segments)	 and	 pan-genome	 (genes	 present	 in	 some	 or	 one	 strain)	 is	 then	
computed	 (187).	 These	 questions	 are	 then	 often	 put	 in	 context	with	metadata	





pan-genomics,	 bacterial	 Genome-Wide	 Association	 Studies	 (GWAS)	 pairing	
phenotypes	with	SNPs,	presence	and	absence	of	genes	and	other	genetic	regions	
like	regulatory	sequences	has	begun	to	emerge	(192–194).		





Comparative	 analyses	 of	 E.	 faecium	 from	 different	 origins	 using	 molecular	
fingerprinting	methods	like	AFLP	and	ribotyping	were	able	to	show	that	E.	faecium	
could	 be	 divided	 by	 which	 hosts	 they	 originate	 from,	 as	 well	 as	 identifying	 a	
subgroup	 associated	 with	 hospital-acquired	 infections	 (195–199).	 An	 MLST	
scheme	for	E.	faecium	was	created	(200),	which	permitted	global	comparisons	of	














performed	 an	 analysis	 aimed	 at	 assessing	 how	much	 recombination	 occurred	
between	 the	different	defined	groups,	 and	 found	 it	 to	occur	 rarely.	The	overall	
conclusion	was	 that	 eBURST-generated	 clusters	were	 indeed	 artificially	 linked.	
They	also	found	association	of	the	nosocomial	CCs	to	STs	originating	from	strains	






suggested	 a	 deep	 division	 between	 strains	 found	 in	 nosocomial	 settings	 and	
elsewhere	 to	 the	point	where	 there	was	 suggested	 to	 create	 a	 new	 subspecies	
based	on	 average	nucleotide	 identity	 (ANI)	 scores	dividing	 this	 clade	 from	 the	
others.	In	all	these	studies,	the	nosocomial	strains	contained	more	resistance-	and	





that	 the	 livestock	 lineage	 departed	 from	 the	 commensal	 lineage	 roughly	 3000	
years	 ago,	 corresponding	 with	 humans	 domesticating	 animals,	 and	 that	 the	
nosocomial	 lineage	 departed	 from	 the	 livestock	 lineage	 within	 a	 decade	 ago,	
parallel	with	the	use	of	antimicrobials.	They	also	found	that	HAIs	tended	to	lack	
CRISPR-cas9	 and	 restriction/modification	 systems,	 commonly	 regarded	 as	
bacterial	 immune	defence	systems	(24),	an	aspect	also	specifically	 investigated	
before	(165,	210).	Further	characteristics	dividing	these	lineages	are	genome	size.	





















vancomycin-resistant	 E.	 faecium	 clone	 spreading	 through	 hospitals	 in	 three	
counties	in	Sweden.		
	
• A	 nosocomially	 adapted	 ST192	 E.	 faecium	 clone	 caused	 an	 outbreak	 in	
Sweden.	The	clone	spread	into	different	hospitals	in	three	counties.		





• This	 plasmid	 was	 able	 to	 transfer	 between	 strains,	 and	 in	 the	 process	
merged	with	a	reppRE25	plasmid	co-localised	in	the	clinical	donor.	After	the	




















• A	 clonal	 outbreak	of	 ST203	E.	 faecium	 occurred	 in	multiple	 hospitals	 in	
Trøndelag,	Norway	
• All	 studied	 isolates	 carried	 the	 vanA	 gene	 cluster	 with	 additional	 IS	
elements	inserted	in	the	intergenic	regions.		




to	 excision	 of	 the	 ISL3	 element	 upstream	 of	 the	 vanHAX	 operon.	 This	

















faecium	donor	 to	 two	E.	 faecium	 recipients	 through	 letting	 the	 element	
hitchhike	with	a	conjugative	reppLG1	megaplasmid.		
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genes	 in	 48	 E.	 faecium	 genomes	 and	 one	 E.	 durans.	 Elements	 residing	
downstream	of	rlmH	and	containing	att	sites	were	extractable	from	25	of	
these	49	genomes.		
• Comparisons	 of	 identified	 elements	 show	 very	 high	 variation	 of	 gene	












2010	 in	 Norway	 and	 Denmark,	 which	 seems	 to	 have	 flattened	 and	 started	
declining	in	Sweden	and	Norway	since	2014.	It	should	be	noted	that	there	have	
occurred	several	outbreaks	 in	 this	period,	and	 that	 these	numbers	also	 include	
identification	 of	 carriers	 during	 outbreak	 investigations,	 which	 outnumber	
clinical	infections.	VRE	were	rarely	encountered	before	the	late	nineties,	and	the	
outbreaks	 of	 VRE	 in	 Scandinavia	 described	 in	 paper	 1,	 paper	 2	 and	 others	





reservoirs	 (227,	 228).	 Another	 important	 pathway	 for	 multi-resistance	
development	 relates	 to	 horizontal	 gene	 transfer	 of	 resistance	 genes	 from	
environmental	 co-inhabitants	 into	 hospital-related	 lineages	 of	 enterococci,	 as	
reported	in	paper	1	and	by	others	(96,	229).		




connected	 to	 BAPS	 group	 2-1,	which	 consisted	 of	 a	mesh	 of	 clinical	 and	 farm-
animal	related	strains.	Pinholt	et	al.	(213,	214)	find	other	single	and	double-locus	






isolates	 as	 the	 foundation	 for	 genetic	 comparison,	 due	 to	 the	 high	 cost	 of	
sequencing	 all	 strains	 at	 those	 time	 points.	 The	WGS	 strains	 were	 thought	 to	
provide	 the	 “prototype”	 of	 the	 strain	 and	 PFGE	 the	 larger	 analysis	 assessing	
relationship	between	strains.		











VVE	 isolate,	 could	 have	 given	 more	 details	 than	 the	 PCRs,	 and	 possibly	 help	
determine	the	whole	sequence	of	the	vanA-containing	plasmid.	HGT	of	the	plasmid	
containing	 the	 silenced	 vanA	 gene	 cluster	 from	 E.	 faecium	 to	 E.	 faecalis	 was	
confirmed	by	S1	nuclease	PFGE	and	Southern	hybridization	of	vanA	and	replicon	
probes.	 We	 knew	 the	 size	 of	 the	 plasmid	 (45-50	 kb),	 but	 only	 22	 kb	 of	 the	
sequence.	 WGS	 analyses	 of	 the	 presumably	 identical	 plasmid	 in	 two	 different	
species	 backgrounds	 could	 possibly	 have	 identified	 the	 rest	 of	 the	 plasmid	
sequence	 by	 DNA	 identity	 scores	 between	 contigs.	 Presently,	 long-read	
technologies	can	close	these	plasmids,	and	would	be	the	superior	alternative.	
Global	 population	 structures	 can	 be	 analysed	 by	 MLST	 (207,	 230),	 but	 only	






Importantly,	 the	 common	 unit	 for	 comparison	 of	 isolates	 has	 become	 the	
sequenced	 genome	 (232).	 Data	 sharing	 on	 a	 global	 scale	 has	 not	 been	
implemented	yet	due	to	challenges	related	to	data	storage,	limitations	in	analytic	
methodology	 and	 speed	 and	 form	 of	 submission	 among	 other	 things,	 see	
Aarestrup	et	al.	(233).	This	opinion	article	highlights	the	potential	for	global	open	
access	to	sequence	data	and	current	initiatives	trying	to	accomplish	this.	Several	
early	 papers	 using	 sequence	 data	 to	 compare	 global	 population	 structures	 in	
bacteria	by	MLST	(for	instance	Maiden	et	al.	(176))	mentioned	portability	as	a	key	
measure	as	assembled	genomic	data	are	contained	in	small	files	which	are	easily	




analysis	 resources,	 which	 may	 provide	 a	 plausible	 pathway	 for	 allowing	 data	
mining	of	complete	data	sets	and	global	surveillance	of	important	pathogens.	
Data	mining	became	an	issue	during	searches	for	ECC	elements	in	paper	3.	We	








done.	 Publication	 of	 assemblies	 may	 become	 more	 common	 as	 long-read	










identify	 likely	origins	 is	 a	 challenging	 task,	 and	present	methods	 seem	 to	have	
issues	with	this.	An	observation	not	mentioned	in	paper	2	was	an	attempt	to	find	
internal	 phylogenetic	 relations	 between	 the	 six	 sequenced	 strains,	 which	
produced	results	too	unlikely	to	be	included	in	the	paper.	We	wanted	to	map	the	
six	 Vancomycin-Variable	 Enterococci	 (VVE)	 to	 Aus0085	 (234)	 which	 was	
genetically	 closest	 according	 to	 the	 parsnp	 WGS	 phylogeny.	 After	 the	 read	
mapping,	 we	 got	 help	 from	 Marc	 Stegger	 at	 the	 Statens	 Serums	 Institut	 in	
Copenhagen	 to	 identify	 probabilistically	 sound	 SNPs	 by	 validation	 through	 the	
GATK	pipeline	 (182).	The	result	 showed	 that	 the	 index	 isolate	was	 identical	 (0	
SNPs)	to	Aus0085,	and	that	the	others	were	separable	to	these	two	strains	by	0-4	
SNPs.	 The	 reads	 from	 our	 sequenced	 strains	 were	 able	 to	 cover	 96%	 of	 the	
Aus0085	 chromosome,	 implying	 that	 these	 isolates	 indeed	 shared	much	of	 the	
chromosome,	and	that	the	chromosomal	DNA	did	not	differ.	The	strong	relation	
was	 highly	 surprising	 as	 Aus0085	was	 isolated	 on	 the	 other	 side	 of	 the	world	
seven	 years	 before	 our	 isolates.	 We	 examined	 the	 accessory	 genome	 through	
Roary	 (190),	 which	 found	 significant	 differences	 in	 gene	 content	 between	
Aus0085	 chromosome	 and	 plasmids	 on	 one	 side,	 and	 our	 fragmented	 VVE	
assemblies	on	the	other.	Subsequently,	we	attempted	to	use	the	cgMLST	scheme	
of	colleagues	in	Utrecht	(212),	where	they	were	able	to	find	that	Aus0085	and	the	




It	 has	 been	 a	 challenge	 to	 create	 a	 comprehensive	 population	 structure	 of	
nosocomial	 E.	 faecium.	 Constructing	 this	 with	 MLST	 data	 using	 the	 eBURST	
algorithm	produced	likely	skewed	results,	and	performing	Bayesian	analyses	on	
the	same	data	(207)	yielded	more	accurate,	but	still	contested	results.	The	present	
consensus	 states	 that	 there	 is	 a	 clear	 distinction	 between	 a	 commensal/	
environmental	lineage	and	a	nosocomial	lineage	(208).	There	has	been	debate	on	
whether	 livestock-	 and	nosocomial	 strains	 are	 actually	 two	 separate	 clades,	 as	
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phylogenetic	distinctions	vary	by	 the	datasets	used	 (23,	24).	 In	addition	 to	 the	




(235)	 suggest	 extensive	 intra-species	 recombination	 as	 a	 prominent	 force	 of	
species	evolution,	and	also	finds	limited	difference	measured	as	single	nucleotide	





ST131	E.	 coli	 found	 in	 different	 environments	 at	 different	 times,	 but	 appeared	
clonal	 by	 SNPs	 extracted	 from	 the	 common	 genetic	 content.	 By	 differentiating	
these	very	similar	genomes	through	accessory	genome	content	and	variations	in	
regulatory	(inter-genic)	regions,	a	better	resolved	population	structure	with	sub-
clusters	 could	 be	 achieved.	 Similar	 analyses	 are	 currently	 being	 pursued	 for	 a	
large	E.	 faecium	dataset	too	(Rob	Willems,	personal	communication),	and	could	
provide	additive	knowledge	here.		
Lastly,	phylogenetic	analyses	 that	also	 take	 into	account	 the	accessory	genome	
could	enhance	how	we	view	outbreaks	and	what	we	regard	as	clinically	important	
transmission	 events.	 Paper	 I	 and	 II	 describe	 that	 resistance	 markers	 are	
horizontally	 transferrable.	 Plasmids	 harbouring	 resistance	 determinants	 may	
transfer	to	create	multi-resistant	strains	which	reduce	treatment	options,	and	may	
crucially	 disturb	 clinical	 decisions	 made	 on	 basis	 of	 whether	 an	 outbreak	 is	
occurring	or	not.	As	Sheppard	et	al.	(238)	found,	rapid	plasmid	dissemination	and	
frequent	 MGE	 rearrangements	 caused	 resistance	 genes	 to	 spread	 into	 several	










As	was	 already	 noted	 in	 the	 epidemiological	 paper	 by	 Söderblom	 et	 al.	 which	
coupled	 paper	 1	 (215),	 the	 Swedish	 guidelines	 performed	 vancomycin	
phenotypic	 susceptibility	 tests	 with	 enrichment	 broth	 containing	 32	 mg/L	




to	 identify	 enterococci	 containing	vanA,	which	phenotypically	 give	 consistently	
higher	MICs.		
Little	 is	 known	 of	 the	 observed	 variability	 of	 vancomycin	 MICs	 in	 E.	 faecium	
containing	vanB,	but	some	studies	exist	on	vanB	activation	by	glycopeptides.	An	
important	feature	of	vanB	is	the	inability	to	be	activated	by	teicoplanin,	thereby	
only	 providing	 resistance	 to	 vancomycin	 (239).	 The	 failure	 of	 vanB	 protection	
against	teicoplanin	exposure	relates	to	presence	of	hydrophobic	moieties	on	this	
glycopeptide	which	 leads	 to	 impaired	 interaction	with	 the	 vanB	 activator	 loop	
(240,	 241).	 Changes	within	VanSB	 has	 previously	 been	 shown	 to	modulate	 the	




escape	 identification	 in	 standardized	 tests	 (244–247),	 making	 this	 issue	
important.		
The	 vancomycin	 resistance	 clusters	 contain	 a	 whole	 pathway	 consisting	 of	
different	 genes,	 and	 changes	 in	 this	 pathway	 is	 likely	 to	 alter	 resistance	






vancomycin	 resistance	operons	are	not	 likely	 to	be	 registered.	Routine	WGS	of	
both	 VSE	 and	 VRE	 for	 international	 pathogen	 surveillance	 has	 not	 been	
implemented	 yet.	 We	 are	 incentivised	 to	 enable	 WGS	 as	 standard	 method	 of	
pathogen	characterization	as	this	better	enables	discovery	of	susceptible	isolates	










may	 exist,	 located	 on	 unknown	 MGEs	 in	 unknown	 bacteria.	 Future	 third-
generation	 sequencing	 technologies	 such	 as	 Oxford	 Nanopore	 may	 improve	
genotypic	 resistance	 determination	 by	 providing	 real-time	 genetic	 content	 in	
addition	to	structural	composition	by	long	reads.	Even	though	a	large	report	by	
Woodford	 et	 al.	 (255)	 recently	 cautioned	 against	 using	 WGS	 in	 general	 for	
antimicrobial	 susceptibility	 testing	 (or	 rather	–	 resistance	 testing)	of	 strains	 in	
clinical	 settings	 as	 the	 technology	 still	 appears	 slightly	 immature,	 testing	 for	
vancomycin	 resistance	 –	 especially	with	 long-read	 technologies	 –	 seems	 like	 a	
good	idea.		
Several	 mechanisms	 may	 contribute	 to	 phenotypic	 vancomycin	 resistance	
variability	in	vanA	and	vanB-containing	strains.	Insertions	of	mobile	elements	into	
gene	clusters	represent	one	pathway,	either	causing	silencing	of	an	operon	(paper	
2)	 or	 providing	 an	 accessory	 promoter	 giving	 constitutive	 expression	 (256).	
Polymerase	slippage	in	promoter	regions	of	vanHAX	may	create	a	better	promoter	
for	un-induced	expression	of	vanHAX	genes	(257).	SNPs	in	the	vancomycin	gene	




in	 diverse	 strains	 or	 species	 can	 cause	 variable	 expression	 of	 vanRS	 and/or	
vanHAX.	Promoter	adaptation	is	likely	to	play	a	role	in	vanB	resistance	operons,	
as	they	frequently	seem	to	transfer	between	anaerobe	species	in	the	gut	and	into	
E.	 faecium	(96).	Also,	vancomycin	 is	shown	to	act	as	a	zinc	chelator	(258).	 It	 is	
unclear	if	Zn(II)-depletion	have	deleterious	effects	on	survival	and/or	replication	
of	 E.	 faecium,	 and	 how	 transport	 and	 retention	 of	 this	 ion	 is	 affected	 by	
vancomycin	exposure.		
A	recent	article	by	San	Millan	et	al.	(259)	assessed	the	evolution	of	the	ampicillin	
resistance	 gene	 blaTEM-1	 on	 the	 chromosome	 or	 a	 small	 multi-copy-number	




the	 quicker	 ceftazidime	 resistance	 development.	 The	 vancomycin	 resistance	
clusters	described	here	(vanA	and	vanB)	are	frequently	harboured	by	plasmids,	as	
seen	in	paper	1	and	paper	2.	The	role	of	plasmids	in	accelerating	the	evolution	of	
plasmid-encoded	 genes	 such	 as	 resistance	 determinants	 could	 further	 be	
addressed	in	enterococci.	For	instance,	in	larger	low-copy-number	plasmids	like	
those	 frequently	 harbouring	 vanA	 or	 vanB,	 other	 adaptations	 may	 be	 at	 play.	
These	 adaptations	 include	 structural	 rearrangements	 of	 genes	 caused	 by	
homologous	 recombination	 and	movement	 of	 replicative	 transposons,	 as	 seen	




Discovery	 of	 horizontal	 gene	 transfer	 of	 particular	 MGEs	 through	 WGS	 is	
precluded	by	short	read	technologies,	as	MGEs	often	become	fragmented	due	to	
presence	of	repeated	regions	such	as	IS	elements	within	them.	E.	faecium	contain	
a	 wealth	 of	 such	 repetitions,	 and	 circularization	 of	 chromosomes	 and	 large	
plasmids	is	thus	impossible	with	short-read	technologies.	Thus,	identification	of	
horizontally	 transferred	genetic	 elements	 is	 currently	often	done	by	 extracting	





plasmid	 harbouring	 vanB	 had	merged	with	 another	 plasmid	 after	 conjugation.	
HGT	and	large	structural	rearrangements	are	not	rare	events	(132,	133),	but	the	
molecular	mechanisms	behind	are	difficult	to	precisely	disentangle	with	PFGE	and	




vanA	 gene	 cluster,	 a	 cat	 chloramphenicol	 resistance	 gene	 and	 other	 plasmid-
related	genes	 in	all	six	sequenced	 isolates,	 the	plasmid	was	 larger,	about	25	kb	
according	 to	 Southern	 hybridization	 of	 S1	 nuclease	 PFGE	 separated	 plasmids.	
Locating	a	possible	source	or	species	distribution	and	degree	of	conservation	in	
genomic	content	of	 this	particular	plasmid	would	have	added	a	strength	 to	 the	
analysis.	 Several	 scientific	 questions	 are	 difficult	 to	 assess	 due	 to	 hampered	
analysis	of	larger	structural	rearrangements.		
One	 of	 the	 principal	 problems	 we	 encountered	 in	 paper	 3	 related	 to	
circularization	of	the	element.	First,	when	we	chose	the	ccrABEnt	containing	strain	
UWECCcat	for	mobilisation	experiments,	we	did	not	know	there	was	a	10	kb	repeat	





any	PCR	product	originating	 from	a	 circularized	ECC.	UWECCcat	was	 thus	not	 a	
suitable	 isolate	 to	 test	 excision	 of	 ECCcat.	 The	 second	 feature	 of	 the	 observed	
duplication	in	UWECCcat	which	created	several	problems,	was	the	duo	of	ISEfm1	
elements	 which	 inconveniently	 also	 was	 present	 in	 the	 reppLG1	 plasmid	 and	
permitted	 homologous	 recombination	 of	 the	 entire	 ECC	 into	 the	 plasmid.	
Remarkably,	if	ISEfm1	would	create	a	circular	excised	composite	transposon	by	
excising	from	UWECCcat	or	the	plasmid	containing	ECCcat,	the	DNA	circle	would	be	















qPCR	 of	 cultured	 cells	 would	 further	 show	 that	 CcrAB	 serine	 recombinases	
recognise	and	recombine	identified	att	sites	in	enterococci	as	well	as	quantifying	









Misiura	 et	 al.	 (264)	 have	 designed	 a	 reporter	 system	 which	 shows	 promise.	
Expression	of	ccrABEnt	in	E.	coli	and	CcrABEnt	action	against	vectors	containing	att	
sites	 could	 show	 action	 of	 CcrABEnt	 on	 att	 sites	 in	 a	 cleaner	 system.	 Properly	
designed	 vectors	 containing	 both	attL/R1	 and	attL/R2	 (see	paper	 3,	 figure	 3)	
could	 determine	 specifically	 whether	 CcrABEnt	 activity	 on	 att	 sites	 occur,	 and	















use	 of	 glycopeptides.	 As	 seen	 by	 the	 global	 resistance	 map	 (Figure	 1)	 and	
prevalence	data	 from	cddep.org,	VRE	are	often	occurring	more	rarely	 than	ECC	
elements.	VRE	from	the	clinical	setting	(as	is	reported	to	the	databases	combined	
in	 cddep.org)	 are	 skewed	 towards	nosocomial	 clades	which	 results	 in	 a	higher	
reported	prevalence	of	vancomycin	resistance	since	commensal	isolates	are	rarely	
VRE.	As	we	 find	ECC	 elements	 throughout	several	environments	and	dispersed	
through	the	whole	E.	faecium	lineage,	it	is	possible	to	state	that	it	is	a	successful	
element	able	to	exist	in	many	different	backgrounds.		
Similarly,	 obtaining	 structural	 information	of	 genomes	 can	extend	 the	 scope	of	
mobile	genetic	elements	from	‘prototypes’	as	public	sequences	now	are,	to	a	larger	




It	 is	 possible	 to	 gain	 knowledge	 by	 shifting	 methods,	 and	 new	 3rd	 generation	
sequencing	technologies	permitting	structural	information	of	genomes	is	likely	to	
allow	a	better	view	of	the	accessory	genome	and	the	structure	of	mobile	elements	
than	 has	 been	 possible	 with	 short-read	 technologies.	 Currently,	 the	
commercialized	technologies	(Pacific	Biosciences	and	Oxford	Nanopore)	are	still	
too	expensive	 to	allow	for	widespread	sequencing	and	closure	of	genomes,	but	
this	may	rapidly	change	as	new	apparatuses	and	SMRTcell/flow	cell	disposables	
with	improved	throughputs	are	released.		
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Another	benefit	of	3rd	generation	sequencers	is	the	addition	of	methylation	data	
to	the	mix	(151),	which	allows	for	analysis	of	R/M	systems.	As	described	earlier,	
R/M	systems	influence	the	dynamics	of	both	host	defence	against	MGEs	and	MGE	
stabilisation	in	prokaryotes.	MGEs	harbouring	R/M	systems	include	ECC,	SCCmec	
and	large	conjugative	plasmids	encoding	resistance	determinants,	and	it	would	be	
interesting	to	experimentally	analyse	whether	these	systems	are	active,	and	if	they	
confer	benefits	to	these	MGEs.		
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